|

Anastrozole Clinical Trials

20 actively recruiting trials across 12 locations

Also known as: Anastrazole, Arimidex, Arimidex®, ICI D1033, ICI-D1033, ZD-1033

Other4 trials

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Phase 2
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

St Louis, Missouri3 trials

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Washington University School of Medicine

Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Washington University School of Medicine

Phase 2

Birmingham, Alabama2 trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 2

Los Angeles, California2 trials

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2

Daphne, Alabama1 trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Southern Cancer Center, PC

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Anchorage, Alaska1 trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Phoenix, Arizona1 trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3

Tucson, Arizona1 trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Fullerton, California1 trial

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

St. Joseph Heritage Healthcare

Phase 2

Washington D.C., District of Columbia1 trial

ETHAN - ET for Male BC

Georgetown University Medical Center

Phase 2

Madison, Wisconsin1 trial

Study of 18F-FFNP Breast PET/MRI

UW Carbone Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.